Parkinson's Disease

TL;DR. Parkinson's disease is the loss of a specific, small population of brain cells: the dopamine-producing neurons of the substantia nigra, a structure the size of a grain of rice. Those cells supply the movement-control circuitry of the basal ganglia, and without enough dopamine, movement becomes slow, small, and stiff, with a tremor at rest. By the time the first tremor appears, roughly 60 to 80 percent of those neurons are already gone. Replacing the missing chemical with levodopa works so well that its introduction in 1967 is one of the genuine miracles of twentieth-century medicine, and its limitations after several years are the central problem of managing the disease. Parkinson's is also more than a movement disorder: constipation, loss of smell, and acting out dreams often appear a decade before any tremor.

Key takeaways

• Over 10 million people live with Parkinson's, and it is the fastest-growing neurological disorder in the world by prevalence, faster than population ageing alone explains.
• The core motor features are bradykinesia (slowness), rigidity, resting tremor, and later postural instability.
• Levodopa remains the most effective drug, more than fifty years after its introduction. Nothing has replaced it.
• Non-motor symptoms often come first: loss of smell, constipation, depression, and REM sleep behaviour disorder can precede diagnosis by 10 to 20 years.
• Dopamine agonists cause impulse control disorders (compulsive gambling, shopping, eating, and hypersexuality) in a meaningful minority of patients. This is common, damaging, frequently not disclosed, and reversible on stopping the drug.
• Exercise is the only intervention with reasonable evidence of modifying the course, and vigorous exercise is now part of standard management rather than an optional extra.

What it is

In short: Slowness plus tremor or rigidity, and it is worth separating Parkinson's disease from the other causes of parkinsonism, which respond differently.

Parkinson's disease is a progressive neurodegenerative disorder defined clinically by bradykinesia plus at least one of resting tremor or rigidity, in the presence of supporting features and the absence of things suggesting an alternative diagnosis.

The classic four, remembered as TRAP:

Parkinsonism is the syndrome; Parkinson's disease is its commonest cause. Other causes matter because they respond differently: drug-induced parkinsonism (antipsychotics, metoclopramide, a common and reversible cause), vascular parkinsonism, and the atypical parkinsonian syndromes (progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration), which progress faster and respond poorly to levodopa.

The history

In short: A London apothecary described it in 1817, dopamine explained it in 1960, and a contaminated street drug in 1982 gave the field its first good model.

In 1817, James Parkinson, a London apothecary-surgeon and political radical, published An Essay on the Shaking Palsy, describing six cases, three of whom he had only observed in the street. His description of "involuntary tremulous motion, with lessened muscular power, in parts not in action... with a propensity to bend the trunk forward, and to pass from a walking to a running pace" is still accurate. Jean-Martin Charcot later added rigidity and bradykinesia, distinguished it from multiple sclerosis, and named it after Parkinson.

What actually goes wrong

In short: A small population of dopamine neurons dies, and symptoms only appear once 60 to 80 percent of them are gone.

The circuit. The basal ganglia act as a gate on movement, with two competing pathways: a direct pathway that facilitates intended movement and an indirect pathway that suppresses competing ones. Dopamine from the substantia nigra tunes both, promoting the direct and inhibiting the indirect. Lose dopamine and the balance shifts toward suppression. The result is exactly what patients describe: movements are not impossible, they are hard to start, small in amplitude, and slow.

The cells. Dopaminergic neurons in the substantia nigra pars compacta die progressively. They are unusually vulnerable: they have enormous, poorly myelinated axonal arbors, they are metabolically demanding, they are autonomously pacemaking with high calcium load, and dopamine metabolism itself generates oxidative stress. Symptoms appear after roughly 60 to 80 percent loss of striatal dopamine, which is why the disease is well established before it is diagnosed.

The protein. Alpha-synuclein, normally a presynaptic protein, misfolds and aggregates into Lewy bodies inside neurons. Aggregated alpha-synuclein appears to spread between connected neurons, templating misfolding in a prion-like manner, though the disease is not transmissible between people.

Where it starts. Braak staging proposes that pathology begins in the olfactory bulb and in the enteric nervous system of the gut, then ascends via the vagus nerve to the brainstem, then to the substantia nigra, then to the cortex. Several observations support this gut-first idea in a subset of patients: constipation and loss of smell often precede motor symptoms by many years, alpha-synuclein pathology is found in gut biopsies, and epidemiological studies have found lower Parkinson's rates in people who had a truncal vagotomy decades earlier. It is a genuinely interesting hypothesis and it is not established for all patients.

What it does to the body

In short: The motor signs are the visible part, and patients frequently rate the non-motor symptoms as more disabling.

Motor: as above, plus shuffling gait with reduced arm swing, festination (accelerating small steps), difficulty turning, freezing of gait (feet feel glued to the floor, particularly at doorways and under time pressure), stooped posture, quiet speech, and swallowing difficulty later, which brings aspiration risk.

Non-motor, which patients frequently rate as more disabling than the motor symptoms:

Is it deadly?

Parkinson's shortens life modestly and is rarely the direct cause of death. People die from its complications: aspiration pneumonia from swallowing failure, injuries from falls, and the general effects of immobility. Modern management, especially treatment of swallowing and falls, has improved life expectancy substantially, and many people live 15 to 20 years or more after diagnosis.

Prevalence is over 10 million worldwide and rising quickly. The Global Burden of Disease analyses show prevalence more than doubling in recent decades, faster than ageing alone predicts, which points to environmental contributors, better diagnosis, or both.

Is it contagious?

No. Parkinson's disease is not transmissible between people by any route.

The prion-like spreading of alpha-synuclein happens within one nervous system and does not imply person-to-person transmission. No evidence of transmission exists in caregivers, spouses, or medical staff.

Who gets it

In short: Age, male sex, pesticide and solvent exposure, head injury, and specific genes, plus two protective associations that nobody can fully explain.

Age: mean onset around 60, rising steeply thereafter. About 5 to 10 percent have young-onset disease before 50, which behaves somewhat differently (slower progression, more dystonia, more drug-induced dyskinesia).

Sex: roughly 1.5 times more common in men.

Environmental exposures with reasonable evidence: pesticides and herbicides (paraquat and rotenone in particular), the industrial solvent trichloroethylene, heavy metals, and repeated traumatic brain injury. Rural living and well water have been associated in several studies, most plausibly through pesticide exposure.

Two protective associations that puzzle everyone: smoking and caffeine are both consistently associated with lower Parkinson's risk. The associations are strong, dose-related, and replicated. Explanations range from a genuine biological effect (nicotine on dopaminergic neurons, caffeine on adenosine receptors) to reverse causation, since prodromal Parkinson's may reduce novelty-seeking and the propensity to become a smoker years before diagnosis. Neither is a recommendation, and smoking would kill vastly more people than it would spare.

Genetics: about 10 to 15 percent of patients have a family history.

• LRRK2 mutations are the commonest known genetic cause, with notably high frequency in Ashkenazi Jewish and North African Berber populations. Penetrance is incomplete.
• GBA variants (the gene that causes Gaucher disease when both copies are affected) are the commonest genetic risk factor, associated with earlier onset and more cognitive decline.
• SNCA (alpha-synuclein), PRKN, PINK1, and DJ-1 cause rarer familial forms, the last three usually with young onset.

Treatment, and how it works

In short: Levodopa replaces the missing chemical and works remarkably well, until after 5 to 10 years the response starts fluctuating.

There is no treatment proven to stop the neurodegeneration. Everything below manages symptoms, and manages them well for many years.

Levodopa

Dopamine cannot cross the blood-brain barrier. Levodopa is its precursor and can. Once in the brain, surviving neurons convert it to dopamine.

The problem is that the same conversion happens in the rest of the body, causing nausea and low blood pressure and wasting most of the dose. So levodopa is always combined with a peripheral decarboxylase inhibitor (carbidopa or benserazide), which blocks that conversion outside the brain but cannot cross into it. That single pharmacological trick is what makes levodopa tolerable and effective, and it is a neat illustration of the blood-brain barrier being used deliberately.

Response is often dramatic, and a good response supports the diagnosis. But after roughly 5 to 10 years, most patients develop motor complications:

• Wearing off: the benefit no longer lasts until the next dose, so symptoms return between doses. As neurons are lost, the brain loses its capacity to store and buffer dopamine, so the effect increasingly tracks the blood level, which fluctuates with each tablet.
• Dyskinesia: involuntary writhing, dance-like movements at peak dose. These are caused by the treatment, not the disease, and patients often prefer being dyskinetic to being frozen.
• On-off fluctuations: sudden, sometimes unpredictable switching between mobility and immobility.

Managing this is the central craft of Parkinson's care: smaller and more frequent doses, controlled-release and extended-release formulations, adding drugs that prolong levodopa's effect, and eventually continuous delivery.

The other drug classes

Device-based and surgical treatment

Deep brain stimulation (DBS): electrodes implanted in the subthalamic nucleus or globus pallidus, connected to a pacemaker-like generator under the collarbone, delivering high- frequency stimulation that disrupts the pathological circuit activity. It substantially reduces off time, tremor, and dyskinesia in appropriately selected patients (those with good levodopa response, troublesome fluctuations, and without significant dementia). It does not treat symptoms that never responded to levodopa, which is a key selection principle and a common source of disappointed expectations.

Focused ultrasound thalamotomy: creates a lesion without opening the skull, guided by MRI, mainly for tremor. Irreversible, and increasingly used in people who cannot or will not have DBS.

Continuous intestinal levodopa gel delivered via a pump into the small intestine, which smooths absorption for patients with severe fluctuations, and newer continuous subcutaneous levodopa formulations.

Non-drug treatment

Exercise, specifically and vigorously. Trials of high-intensity treadmill exercise and programmes such as amplitude-focused training (LSVT BIG) show improvements in motor function beyond what deconditioning explains, and animal work suggests neuroprotective mechanisms. Boxing-style, dance, and tai chi programmes have evidence for balance and quality of life. This is the closest thing to disease modification currently available.

Physiotherapy for gait and falls, using cueing (a metronome, counting, stepping over a line, a laser pointer on a walking stick) to bypass the failing internal timing signal, which often works remarkably well for freezing.

Speech and language therapy (LSVT LOUD) for voice volume, and for swallowing safety. Occupational therapy for daily function.

What treatment costs

In short: Dopamine agonists cause compulsive gambling, shopping, and sexual behaviour in a meaningful minority, and patients are rarely warned.

• Levodopa: nausea (reduced by taking with food, though protein competes with its absorption), low blood pressure, sleepiness, hallucinations at higher doses, and after years, dyskinesia and fluctuations.
• Dopamine agonists: this is the one to know about. Impulse control disorders (pathological gambling, compulsive shopping, binge eating, hypersexuality) occur in a substantial minority of patients on agonists, more in younger men and those with prior impulsivity. People have lost houses and marriages to a side effect that was never explained to them, and patients rarely volunteer these behaviours. Every patient and family should be told before the drug is started and asked about it at each review. It usually resolves when the drug is reduced or stopped. Agonists also cause sudden-onset sleep attacks (with implications for driving), leg swelling, and hallucinations.
• Anticholinergics: confusion, memory impairment, dry mouth, urinary retention, and worsened glaucoma.
• DBS: surgical risks including bleeding and infection, hardware problems, speech and balance side effects, and mood changes.
• Antipsychotics used for hallucinations must be chosen carefully; most worsen parkinsonism badly. Quetiapine, clozapine, and pimavanserin are the exceptions.

What the person can do

In short: Exercise hard and early, take medication exactly on time, and treat the constipation and blood pressure drops that cause most of the day-to-day trouble.

• Exercise vigorously and regularly, and start early. This is the single strongest recommendation in the chapter.
• Take medication on time, to the minute. Parkinson's drug timing is unusually strict, and a delayed dose means a real loss of function. This matters most in hospital, where "drug rounds" schedules routinely mismatch a patient's regimen, a recognised safety problem that patients and families should raise explicitly on admission.
• Take levodopa away from protein-heavy meals if absorption is erratic, since dietary amino acids compete for the same transporter.
• Treat constipation actively. It is nearly universal, it makes drug absorption worse, and it is under-managed.
• Fall-proof the home and work with a physiotherapist on cueing strategies for freezing.
• Ask about impulse control and tell someone if it is happening. It is a drug effect, not a character flaw.
• Speech therapy early, before the voice becomes hard to understand.
• Watch blood pressure on standing, since orthostatic hypotension causes many falls and is treatable.

Living with it

Parkinson's is visible in a way most diseases are not, and the visibility carries social cost: people are assumed to be drunk, or cognitively impaired, or unfriendly because of the reduced facial expression, which is a mechanical consequence of the disease and is regularly misread as coldness or depression.

The fluctuating course is its own difficulty. Someone can be capable at 10 a.m. and unable to rise from a chair at noon, which is hard for employers, families, and benefits assessors to accept as a single condition.

Depression and apathy are common, intrinsic to the disease rather than merely reactive, and treatable. Apathy in particular is often mistaken by families for laziness or for depression, and it responds differently.

What's next

In short: Cell replacement, gene-specific drugs, and tests that detect the misfolded protein years before symptoms appear.

• Alpha-synuclein targeting: antibodies against aggregated alpha-synuclein have so far failed to slow progression in phase 2 trials, which was a significant disappointment. Other approaches (aggregation inhibitors, vaccines, reducing production) continue.
• GLP-1 receptor agonists: after a promising phase 2 signal for exenatide, a larger phase 3 trial reported no benefit, which is a useful reminder about phase 2 results.
• Cell replacement. Stem-cell-derived dopamine neurons transplanted into the striatum have entered clinical trials, with early reports of graft survival and dopamine production. This is the most conceptually direct approach: put the missing cells back.
• Gene therapy, delivering genes for dopamine-synthesising enzymes or growth factors.
• Precision approaches by genotype, notably LRRK2 inhibitors and GBA-targeted therapies, which are the first attempts to treat a genetically defined subgroup.
• Seed amplification assays on spinal fluid and skin biopsy, which detect misfolded alpha-synuclein with high accuracy and are turning Parkinson's into a biologically diagnosable disease rather than a purely clinical one. That in turn makes early intervention trials possible, in people with REM sleep behaviour disorder for example, years before motor symptoms.

Sources and notes

Prevalence and growth: Global Burden of Disease neurological disorders analyses; over 10 million people affected, with Parkinson's described as the fastest-growing neurological disorder. James Parkinson, An Essay on the Shaking Palsy, 1817. Dopamine depletion: Ehringer and Hornykiewicz, 1960. Levodopa: Cotzias et al., NEJM, 1967. MPTP: Langston et al., Science, 1983. Alpha-synuclein in familial Parkinson's: Polymeropoulos et al., Science, 1997. Braak staging: Braak et al., Neurobiology of Aging, 2003. Vagotomy and Parkinson's risk: Svensson et al., Annals of Neurology, 2015. Impulse control disorders with dopamine agonists: Weintraub et al., Archives of Neurology, 2010 (found in roughly 14 percent of patients on agonists in a large cross-sectional study). Exercise: SPARX and related trials. Exenatide phase 3: reported 2024. Seed amplification assays: Siderowf et al., Lancet Neurology, 2023.

Open questions. Whether the gut-first hypothesis applies to all patients or defines a subtype is unresolved. Why smoking and caffeine are protective is not settled. No disease-modifying therapy has yet succeeded.

Next: the disease of sudden electrical storms, and the one most burdened by ancient misunderstanding. 👉